{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:38:47Z","timestamp":1792431527250,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejmech.2024.116428","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T02:11:57Z","timestamp":1713406317000},"page":"116428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Benzothiazole derivatives as histone deacetylase inhibitors for the treatment of autosomal dominant polycystic kidney disease"],"prefix":"10.1016","volume":"271","author":[{"given":"Xudong","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6142-4825","authenticated-orcid":false,"given":"Dong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116428_bib1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","article-title":"Polycystic kidney disease","volume":"4","author":"Bergmann","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.ejmech.2024.116428_bib2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2024.116428_bib3","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1681\/ASN.2018050493","article-title":"Prevalence estimates of polycystic kidney and liver disease by population sequencing","volume":"29","author":"Lanktree","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejmech.2024.116428_bib4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ki.2009.128","article-title":"Autosomal dominant polycystic kidney disease: the last 3 years","volume":"76","author":"Torres","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejmech.2024.116428_bib5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ndt\/gfy297","article-title":"Pro: tolvaptan delays the progression of autosomal dominant polycystic kidney disease","volume":"34","author":"Torres","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejmech.2024.116428_bib6","unstructured":"US Food & Drug Administration. Warning: Risk of Serious Liver Injury. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/204441lbl.pdf (accessed April 10, 2022)."},{"key":"10.1016\/j.ejmech.2024.116428_bib7","unstructured":"European Medicines Agency. Risk Management Plan for Tolvaptan. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jinarc-epar-product-information_en.pdf (accessed April 10, 2022)."},{"key":"10.1016\/j.ejmech.2024.116428_bib8","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.bbadis.2010.10.008","article-title":"Epigenetics and autosomal dominant polycystic kidney disease","volume":"1812","author":"Li","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2024.116428_bib9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ki.2011.296","article-title":"Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation","volume":"81","author":"Fan","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejmech.2024.116428_bib10","article-title":"HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2024.116428_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s10020-018-0027-4","article-title":"Inhibition of HDAC6 activity in kidney diseases: a new perspective","volume":"24","author":"Ke","year":"2018","journal-title":"Mol. Med."},{"key":"10.1016\/j.ejmech.2024.116428_bib12","doi-asserted-by":"crossref","first-page":"F997","DOI":"10.1152\/ajprenal.00186.2017","article-title":"An inhibitor of histone deacetylase 6 activity, ACY-1215, reduces cAMP and cyst growth in polycystic kidney disease","volume":"313","author":"Yanda","year":"2017","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejmech.2024.116428_bib13","doi-asserted-by":"crossref","first-page":"21819","DOI":"10.1073\/pnas.0911987106","article-title":"Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models","volume":"106","author":"Cao","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2024.116428_bib14","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1186\/s12885-018-4965-6","article-title":"Analysis of oncogenic activities of protein kinase D1 in head and neck squamous cell carcinoma","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejmech.2024.116428_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/med.20200","article-title":"Histone deacetylase inhibitors (HDACIs). Structure--activity relationships: history and new QSAR perspectives","volume":"32","author":"Pontiki","year":"2012","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2024.116428_bib16","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1021\/acs.jmedchem.1c02225","article-title":"Discovery of DNA-targeting HDAC inhibitors with potent antitumor efficacy in vivo that trigger antitumor immunity","volume":"65","author":"Chen","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116428_bib17","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1021\/acs.jmedchem.1c01863","article-title":"Discovery of novel histone deacetylase 6 (HDAC6) inhibitors with enhanced antitumor immunity of anti-PD-L1 immunotherapy in melanoma","volume":"65","author":"Peng","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116428_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114634","article-title":"Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity","volume":"241","author":"Chen","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116428_bib19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00109-010-0715-1","article-title":"Formation of cysts by principal-like MDCK cells depends on the synergy of cAMP- and ATP-mediated fluid secretion","volume":"89","author":"Buchholz","year":"2011","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ejmech.2024.116428_bib20","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/aps.2011.29","article-title":"Drug discovery for polycystic kidney disease","volume":"32","author":"Sun","year":"2011","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2024.116428_bib21","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.kint.2017.04.013","article-title":"Ganoderma triterpenes retard renal cyst development by downregulating Ras\/MAPK signaling and promoting cell differentiation","volume":"92","author":"Su","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejmech.2024.116428_bib22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2011.267","article-title":"Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy","volume":"31","author":"Spiegel","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2024.116428_bib23","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.3390\/ijms24054720","article-title":"Selectivity of hydroxamate- and difluoromethyloxadiazole-based inhibitors of histone deacetylase 6 in vitro and in cells","volume":"24","author":"Ptacek","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116428_bib24","doi-asserted-by":"crossref","first-page":"7039","DOI":"10.1158\/1078-0432.CCR-06-1802","article-title":"A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer","volume":"12","author":"Rubin","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116428_bib25","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1128\/MCB.01154-06","article-title":"Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally","volume":"28","author":"Zhang","year":"2008","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2024.116428_bib26","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.tips.2014.08.001","article-title":"Drugging the HDAC6-HSP90 interplay in malignant cells","volume":"35","author":"Kramer","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2024.116428_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103960","article-title":"Design, synthesis and evaluation of benzothiazole derivatives as multifunctional agents","volume":"101","author":"Djuidje","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.116428_bib28","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1021\/acs.jmedchem.1c00413","article-title":"Efficient synthesis and bioevaluation of novel dual tubulin\/histone deacetylase 3 inhibitors as potential anticancer agents","volume":"64","author":"Peng","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116428_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173157","article-title":"Revisit ligand-receptor interaction at the human vasopressin V2 receptor: a kinetic perspective","volume":"880","author":"Liu","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116428_bib30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.kint.2016.01.026","article-title":"Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease","volume":"90","author":"Cebotaru","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejmech.2024.116428_bib31","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/2211-5463.13459","article-title":"PF-06409577 inhibits renal cyst progression by concurrently inhibiting the mTOR pathway and CFTR channel activity","volume":"12","author":"Su","year":"2022","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.ejmech.2024.116428_bib32","doi-asserted-by":"crossref","first-page":"7717","DOI":"10.1021\/acs.jmedchem.2c00011","article-title":"Long residence time at the vasopressin V2 receptor translates into superior inhibitory effects in ex vivo and in vivo models of autosomal dominant polycystic kidney disease","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424003088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424003088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T09:34:48Z","timestamp":1717234488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424003088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":32,"alternative-id":["S0223523424003088"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116428","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benzothiazole derivatives as histone deacetylase inhibitors for the treatment of autosomal dominant polycystic kidney disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116428","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116428"}}